 Pharmacor --
May 2005
 You Need to Know
Several novel therapeutic classes
(e.g., CCR5 antagonists, integrase inhibitors) are in development for HIV. What
are physician perceptions regarding these emerging classes for HIV? How will
these agents be positioned in future HIV treatment? What is the commercial
outlook for these classes? What portfolio management and inlicensing strategies
should companies pursue to attain leadership positions in the HIV market?
Introduction
HIV treatment is at a crossroads;
the significant investment in HIV R&D over the past 15 years is bearing
fruit with a host of new agents offering novel approaches. These novel
antiretroviral classes--CCR5 and CXCR4 antagonists, integrase inhibitors,
gp120 attachment inhibitors, gp41 fusion inhibitors, and viral
maturation/assembly inhibitors--have the potential to address key unmet
needs in the treatment of HIV and dramatically expand the market.
Key Findings
 In 2004, the prevalence of HIV exceeded 1.5 million cases in the
seven major pharmaceutical markets under study; this figure will expand to more
than 2 million cases by 2019. The introduction of novel classes of drugs for
HIV will drive sales up considerably from the 2004 figure of $6.8 billion.
As drug resistance increases among HIV patients, there is an
urgent need for novel products that are active against drug-resistant HIV, as
well as for better tolerated and safer therapies.
Over the next 10-15 years, currently marketed antiretroviral classes
will face significant competition from novel classes, which will be important
drivers of growth.
The chemokine coreceptor CCR5 and the enzyme integrase are
emerging as the most promising targets for development.
Why Buy This Report?
Identify portfolio strategies for attaining a leadership position
in HIV treatment.
Explore the commercial potential and positioning of emerging HIV
classes.
Evaluate the advantages and risks of drug development in HIV.
|
